We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

EMA Green Lights Accelerated Program for RNAi Therapeutic

News   Mar 02, 2017 | Original story Alnylam

 
EMA Green Lights Accelerated Program for RNAi Therapeutic

Credit: EMA

 
 
Advertisement
 

RELATED ARTICLES

Oxford's COVID-19 Vaccine Has 70% Efficacy Rate

News

There are now over 170 teams of researchers working to develop a vaccine for protection against COVID-19. Over the last few weeks, a number of groups shared interim analysis data on candidates that have reached Phase III clinical testing. The latest addition is the University of Oxford – in collaboration with the pharmaceutical company AstraZeneca – who today announce an efficacy of 70.4% for the candidate, ChAdOx1 nCoV-2019.

READ MORE

Two Targeted Therapies Developed for Idiopathic Pulmonary Fibrosis

News

A new treatment option for lung fibrosis is being developed by Purdue University scientists.

READ MORE

Sputnik V COVID-19 Vaccine Has Efficacy Rate of 92%, Interim Analysis Suggests

News

The Gamaleya Center and the Russian Direct Investment Fund have announced that Sputnik V – the world's first registered vaccine against COVID-19 – demonstrates an efficacy rate of ~92%.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE